Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)

Papaioannou, Andriana Ι.; Κostikas, Κonstantinos; Papadaki, Georgia; Roussou, Aneza; Spathis, Aris; Mazioti, Argyro; Tomos, Ioannis; Manali, Effrosyni D.; Loukides, Stelios; Karakitsos, Petros; Papiris, Spyros; Diamantea, Filia

doi:10.1183/13993003.congress-2015.oa3512

Cited by 2 publications

(5 citation statements)

References 52 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our protein signature comprised of SFTPB, ALDOA, HMGB1, CALML5 and TLN1. SFTPB levels in serum of IPF patients are known to be elevated 32 and are associated with poor survival 33 .…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

A novel protein signature from plasma extracellular vesicles for non-invasive differential diagnosis of idiopathic pulmonary fibrosis

Adduri

Cai

et al. 2021

Preprint

View full text Add to dashboard Cite

Background: Idiopathic pulmonary fibrosis (IPF) is a fibrosing interstitial pneumonia of unknown etiology often leading to respiratory failure. Over half of IPF patients present with discordant features of usual interstitial pneumonia on high-resolution computed tomography at diagnosis which warrants surgical lung biopsy to exclude the possibility of other interstitial lung diseases (ILDs). Therefore, there is a need for non-invasive biomarkers for expediting the differential diagnosis of IPF. Methods: Using mass spectrometry, we performed proteomic analysis of plasma extracellular vesicles (EVs) in a cohort of subjects with IPF, chronic hypersensitivity pneumonitis, nonspecific interstitial pneumonitis, and healthy subjects (HS). A five-protein signature was identified by lasso regression and was validated in an independent cohort using ELISA. We evaluated the concordance between plasma EV proteome and the lung transcriptome data. Lastly, we compared the molecular pathways overrepresented in IPF by differentially expressed proteins and transcripts from EVs and lung tissues, respectively. Results: The five-protein signature derived from mass spectrometry data showed area under the receiver operating characteristic curve of 0.915 (95%CI: 0.819-1.011) and 0.958 (95%CI: 0.882-1.034) for differentiating IPF from other ILDs and from HS, respectively. We also found that the EV protein expression profiles mirrored their corresponding mRNA expressions in IPF lungs. Further, we observed an overlap in the EV proteome- and lung mRNA-associated molecular pathways. Conclusions: We discovered a plasma EV-based protein signature for differential diagnosis of IPF and validated this signature in an independent cohort. The signature needs to be tested in large prospective cohorts to establish its clinical utility.

show abstract

“…Our protein signature comprised of SFTPB, ALDOA, HMGB1, CALML5 and TLN1. SFTPB levels in serum of IPF patients are known to be elevated 32 and are associated with poor survival 33 .…”

Section: Discussionmentioning

confidence: 99%

“…Our protein signature comprised of SFTPB, ALDOA, HMGB1, CALML5 and TLN1. SFTPB levels in serum of IPF patients are known to be elevated 32 and are associated with poor survival 33 . Similarly, proteomic analysis of broncho-alveolar lavage fluid (BALF) revealed upregulation of ALDOA in IPF patients presented with acute exacerbations 34 .…”

Section: Discussionmentioning

confidence: 99%

A novel protein signature from plasma extracellular vesicles for non-invasive differential diagnosis of idiopathic pulmonary fibrosis

Adduri

Cai

et al. 2021

Preprint

View full text Add to dashboard Cite

show abstract

“…Ultimately, 13 publications met the inclusion criteria and were included in the meta-analysis. [8][9][10][11][12][13][14][15][16][17][18][19][20] Detailed characteristics of the included trials are shown in Table 1. The 13 studies contained a total of 1710 participants (603 in the CPFE group and 1107 in the IPF alone group) published between 2009 and 2017.…”

Section: Study Identificationmentioning

confidence: 99%

“…The 13 studies contained a total of 1710 participants (603 in the CPFE group and 1107 in the IPF alone group) published between 2009 and 2017. Two of the trials were conducted in Europe, 18,20 two in North America, 8,11 and the remaining nine trials in east Asia. 9,10,[12][13][14][15][16][17]19 The number of participants in each study ranged from 17 to 365 individuals.…”

Section: Study Identificationmentioning

confidence: 99%

See 1 more Smart Citation

Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone

Jiang

Zheng

2019

Ther Adv Respir Dis

View full text Add to dashboard Cite

Background:Combined pulmonary fibrosis and emphysema (CPFE) is a syndrome characterized by the coexistence of upper lobe emphysema and lower lobe fibrosis. However, whether CPFE has a higher or lower mortality than idiopathic pulmonary fibrosis (IPF) alone is still not clear. In this study we conducted a meta-analysis to assess the survival rate (SR) of CPFE versus IPF alone in clinical trials.Methods:We performed a systematic search of PubMed, Embase, and the Cochrane Central Register of Controlled Trials for trials published prior to 31 March 2018. Extracts from the literature were analyzed with Review Manager version 5.3.Results:Thirteen eligible trials were included in this analysis (involving 1710 participants). Overall, the pooled results revealed that no statistically significant difference was detected in the 1-year [relative risk (RR) = 0.98, 95% confidence interval (CI): 0.94–1.03, p = 0.47], 3-year (RR = 0.83, 95% CI: 0.68–1.01, p = 0.06), and 5-year (RR = 0.80, 95% CI: 0.59–1.07, p = 0.14) SRs of CPFE versus IPF alone.Conclusions:CPFE exhibits a very poor prognosis, similar to IPF alone. Additional studies are needed to provide more convincing data to investigate the natural history and outcome of patients with CPFE in comparison to IPF. The reviews of this paper are available via the supplemental material section.

show abstract

Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE)

Abstract: Introduction

Cited by 2 publications

References 52 publications

A novel protein signature from plasma extracellular vesicles for non-invasive differential diagnosis of idiopathic pulmonary fibrosis

A novel protein signature from plasma extracellular vesicles for non-invasive differential diagnosis of idiopathic pulmonary fibrosis

Prognosis of combined pulmonary fibrosis and emphysema: comparison with idiopathic pulmonary fibrosis alone

Contact Info

Product

Resources

About